Mark Lipitz, DO
Neurology · Altoona, PANPI 1649240318
Payments from drug & device makers
What this record shows
This record is dominated by education: $482 of the $623 with a category attached, or 77.4%. Teva Pharmaceuticals USA, Inc. accounts for 65.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $227 and has fallen 78.4% since, to $49 in 2025. That places this record below the midpoint for neurology clinicians in PA, where the typical reported total is $778.
Across 13 payments — averaging $47.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$410
- Genentech, Inc.$90
- Avadel CNS Pharmaceuticals, LLC$25
- Inspire Medical Systems, Inc.$24
- Harmony Biosciences LLC$24
- Livanova USA, Inc.$20
- plus $29 from 2 others
What the payments were for
- Food & beverage$14123%
- Education$48277%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $410 |
| Genentech, Inc. | 2 | $90 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Harmony Biosciences LLC | 1 | $24 |
| Livanova USA, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $13 |
How this compares
$623 in reported general payments places this provider in the 45th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 11 | $246,709 |
| Gabapentin | 18 | $330 |
| Ropinirole Hcl | 20 | $88 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Other neurology in Altoona
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.